Amylyx Pharmaceuticals, Inc.AMLXEarnings & Financial Report
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.
Revenue
$416.0K
Gross Profit
N/A
Operating Profit
$-75.7M
Net Profit
$-72.7M
Gross Margin
N/A
Operating Margin
-18187.7%
Net Margin
-17476.9%
YoY Growth
-99.6%
EPS
$-1.07
Amylyx Pharmaceuticals, Inc. Q3 FY2024 Financial Summary
Amylyx Pharmaceuticals, Inc. reported revenue of $416.0K (down 99.6% YoY) for Q3 FY2024, with a net profit of $-72.7M (down 448.0% YoY) (-17476.9% margin).
Key Financial Metrics
| Total Revenue | $416.0K |
|---|---|
| Net Profit | $-72.7M |
| Gross Margin | N/A |
| Operating Margin | -18187.7% |
| Report Period | Q3 FY2024 |
Amylyx Pharmaceuticals, Inc. Annual Revenue by Year
Amylyx Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $0).
| Year | Annual Revenue |
|---|---|
| 2025 | $0 |
| 2024 | $87.4M |
| 2023 | $380.8M |
Amylyx Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
Amylyx Pharmaceuticals, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $-33.0M | N/A |
| Q3 FY2025 | $0 | — | $-34.4M | N/A |
| Q2 FY2025 | $0 | — | $-41.4M | N/A |
| Q1 FY2025 | $0 | — | $-35.9M | N/A |
| Q4 FY2024 | $-665.0K | -100.6% | $-37.5M | 5646.0% |
| Q3 FY2024 | $416.0K | -99.6% | $-72.7M | -17476.9% |
| Q2 FY2024 | $-1.0M | -101.0% | $-72.7M | 7106.5% |
| Q1 FY2024 | $88.6M | +24.1% | $-118.8M | -134.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $88.6M | $-1.0M | $416000 | $-665000 | $0 | $0 | $0 | $0 |
| YoY Growth | 24.1% | -101.0% | -99.6% | -100.6% | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $417.5M | $332.2M | $250.7M | $193.6M | $219.7M | $194.6M | $362.7M | $332.6M |
| Liabilities | $93.0M | $70.9M | $54.5M | $28.9M | $18.3M | $26.7M | $30.7M | $27.4M |
| Equity | $324.4M | $261.3M | $196.2M | $164.8M | $201.4M | $167.9M | $332.0M | $305.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-489000 | $-66.6M | $-41.6M | $-59.0M | $-39.8M | $-25.2M | $-30.4M | $-27.9M |